title: Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.
abstract: Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.
authors.affiliation: Sinai Center for Thrombosis Research, Baltimore, MD, USA.
authors.forename: Kevin P
authors.initials: KP
authors.lastname: Bliden
authors.affiliation: New Haven Pharmaceuticals, Inc., North Haven, CT, USA.
authors.forename: Jeff
authors.initials: J
authors.lastname: Patrick
authors.affiliation: New Haven Pharmaceuticals, Inc., North Haven, CT, USA.
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Pennell
authors.affiliation: Sinai Center for Thrombosis Research, Baltimore, MD, USA.
authors.forename: Udaya S
authors.initials: US
authors.lastname: Tantry
authors.affiliation: Sinai Center for Thrombosis Research, Baltimore, MD, USA.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Gurbel
mesh_terms: D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003692:Delayed-Action Preparations / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D055502:Secondary Prevention
chemical_list: D003692:Delayed-Action Preparations; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
keywords: Durlaza; acetylsalicylic acid; antiplatelet; cardiovascular disease; diabetes; extended-release; microcapsule; secondary prevention; thrombosis